The digital therapeutics market is slated to reach $56B by 2025 – here's how payers, pharma, and others stand to benefit from partnering with this new tech

DIGITAL HEALTH REPORT PREVIEW The Teladoc-Livongo megamerger put a spotlight on the power of digital therapies—here are the most innovative players racing to catch up as the pandemic vaults the market to reach $56 billion by 2025 * This chart and data were pulled from the Digital Therapeutics Report by Insider Intelligence. Purchase the report here to get immediate access to the full analysis. Get the Full Analysis Today → Digital therapeutics (DTx) were gaining popularity as tools to help slash the US' $3 trillion annual spending on chronic disease. As the pandemic induced rapid growth in the DTx market, Teladoc merged with DTx firm Livongo in an $18.5 billion blockbuster deal—forming the first-ever virtual care giant and threatening to overshadow smaller digital health startups. Now, the global DTx market is forecast to jump from a $5.8 billion to a $56 billion global opportunity by 2025. Players are racing to capture a slice of the market — here's how patients, providers, and payers could benefit from partnering with or acquiring a DTx firm: Payer-DTx alliances are mutually beneficial: Payers give DTx firms access to larger patient populations and payers can use DTx to minimize the economic burden of chronic disease. For context, the US spends $3.2 trillion on chronic disease costs annually, and this spending is largely due to preventable disease—and this figure is projected to only trend upward. DTx platforms present pharma companies with opportunities to both augment their existing drug portfolio and pry open revenue streams beyond traditional drugs. For context, more than 80% of the US' $3.4 trillion healthcare costs are spent on diseases that are modifiable or reversible through behavior changes, according to insights from McKinsey. DTx should help telehealth vendors improve health outcomes, and in turn prop up the value of their product to patients and payers. Considering that 93% of physicians are already using telehealth for chronic care check-ins—per the 2020 Amwell Physician and Consumer Survey—incorporating innovative solutions like DTx can... Access Full Chart Data & Analysis → Other report highlights you don't want to miss… The AI in Drug Discovery and Development Report The pharmaceutical industry has been lagging behind other industries when it comes to digitization, but… Access Full Report → The Digital Health Startups to Watch Report An inside look at the top US startups transforming healthcare through AI, telehealth, and medical devices… Access Full Report → This is just a preview of the information and insights you'll find in The Digital Therapeutics Report by Insider Intelligence. Purchase the report today to access the full analysis. Get The Full Report for $995 →

Email sent to: nguyenvu1187.love5@blogger.com Manage your email preferences  |  Unsubscribe  |  Terms of Service  |  Privacy Policy © 2021 Insider Intelligence, 11 Times Square, 14th FL, New York, NY 10036